Acquired by Eli Lilly in December 2022
AKUS - Akouos, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
AKUS price evolution
AKUS
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.86 | $76.03 | $56.83 | $124.36 |
| Short term investments | $93.92 | $119.31 | $154.72 | $110.55 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $174.49 | $194.92 | $211.45 | $236.16 |
| Long term investments | ||||
| Property, plant & equipment | $48.54 | $47.14 | $42.02 | $40.14 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $51.02 | $49.62 | $44.51 | $42.59 |
| Total investments | $93.92 | $119.31 | $154.72 | $110.55 |
| Total assets | $225.51 | $244.54 | $255.96 | $278.75 |
| Current liabilities | ||||
| Accounts payable | $0.56 | $0.68 | $1.33 | $1.28 |
| Deferred revenue | ||||
| Short long term debt | $0.79 | $0.75 | $0.71 | $0.67 |
| Total current liabilities | $10.09 | $14.59 | $18.56 | $16.8 |
| Long term debt | $34.58 | $32 | $28.41 | $28.3 |
| Total noncurrent liabilities | $34.58 | $32 | $28.41 | $28.3 |
| Total debt | $35.37 | $32.74 | $29.13 | $28.98 |
| Total liabilities | $44.67 | $46.59 | $46.97 | $45.1 |
| Shareholders' equity | ||||
| Retained earnings | -$236.05 | -$216.21 | -$195.38 | -$168.4 |
| Other shareholder equity | -$0.74 | -$0.91 | -$0.73 | -$0.2 |
| Total shareholder equity | $180.84 | $197.95 | $208.98 | $233.65 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $124.36 | $70.25 | $26.39 | $24.34 |
| Short term investments | $110.55 | $239.08 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $236.16 | $310.64 | $26.14 | $23.34 |
| Long term investments | ||||
| Property, plant & equipment | $40.14 | $21.35 | $17.71 | $1.12 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $42.59 | $22.71 | $19.02 | $2.44 |
| Total investments | $110.55 | $239.08 | ||
| Total assets | $278.75 | $333.35 | $45.16 | $25.78 |
| Current liabilities | ||||
| Accounts payable | $1.28 | $0.9 | $0.34 | $0.43 |
| Deferred revenue | ||||
| Short long term debt | $0.67 | $1.11 | $0.64 | |
| Total current liabilities | $16.8 | $10.71 | $5.94 | $4.93 |
| Long term debt | $28.3 | $12.03 | $13.14 | |
| Total noncurrent liabilities | $28.3 | $12.03 | $13.33 | $0.42 |
| Total debt | $28.98 | $13.14 | $13.78 | |
| Total liabilities | $45.1 | $22.74 | $19.27 | $5.36 |
| Shareholders' equity | ||||
| Retained earnings | -$168.4 | -$81.72 | -$33.12 | -$7.38 |
| Other shareholder equity | -$0.2 | $0.01 | ||
| Total shareholder equity | $233.65 | $310.61 | -$32.8 | -$7.23 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $13.94 | $14.32 | $20.39 | $18.82 |
| Selling, general & administrative | $6.27 | $6.68 | $6.65 | $6.16 |
| Total operating expenses | $20.2 | $21 | $27.03 | $24.98 |
| Operating income | -$20.2 | -$21 | -$27.03 | -$24.98 |
| Income from continuing operations | ||||
| EBIT | -$19.84 | -$20.83 | -$26.98 | -$24.94 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$19.84 | -$20.83 | -$26.98 | -$24.94 |
| Income (for common shares) | -$19.84 | -$20.83 | -$26.98 | -$24.94 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $64.59 | $34.3 | $20.47 | $5.64 |
| Selling, general & administrative | $22.23 | $14.58 | $3.41 | $1.78 |
| Total operating expenses | $86.82 | $48.88 | $23.88 | $7.42 |
| Operating income | -$86.82 | -$48.88 | -$23.88 | -$7.42 |
| Income from continuing operations | ||||
| EBIT | -$86.67 | -$48.6 | -$25.74 | -$6.01 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$86.67 | -$48.6 | -$25.74 | -$6.01 |
| Income (for common shares) | -$86.67 | -$48.6 | -$25.74 | -$6.01 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$19.84 | -$20.83 | -$26.98 | -$24.94 |
| Operating activities | ||||
| Depreciation | $1.02 | $1.12 | $0.92 | $1.03 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.5 | $2.76 | $2.63 | $2.54 |
| Total cash flows from operations | -$21.1 | -$16.98 | -$20.06 | -$15.94 |
| Investing activities | ||||
| Capital expenditures | -$2.6 | -$6.25 | -$2.79 | -$0.91 |
| Investments | $25.57 | $35.13 | -$44.89 | $24.01 |
| Total cash flows from investing | $22.96 | $28.88 | -$47.69 | $23.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.03 | $7.29 | $0.22 | $0.01 |
| Net borrowings | ||||
| Total cash flows from financing | -$0.03 | $7.29 | $0.22 | $0.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.83 | $19.2 | -$67.53 | $7.28 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$86.67 | -$48.6 | -$25.74 | -$6.01 |
| Operating activities | ||||
| Depreciation | $3.75 | $2.17 | $0.7 | $0.06 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.48 | $4.5 | $0.14 | $0.02 |
| Total cash flows from operations | -$63.73 | -$40.77 | -$19.51 | -$6.74 |
| Investing activities | ||||
| Capital expenditures | -$9.02 | -$4.53 | -$3.44 | -$0.53 |
| Investments | $126.64 | -$239.35 | ||
| Total cash flows from investing | $117.62 | -$243.88 | -$3.44 | -$0.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.41 | $223.92 | $0.09 | $0.08 |
| Net borrowings | -$0.19 | -$0.25 | -$0.1 | -$0.02 |
| Total cash flows from financing | $0.22 | $328.5 | $25 | $24.85 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $54.11 | $43.85 | $2.06 | $17.58 |
News
|
10 Most Promising Gene Therapy Companies to Watch
Insider Monkey via Yahoo Finance
14 Nov 2022
|
|
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Entrpreneur
27 Oct 2022
|
|
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie
Zacks via Yahoo Finance
24 Oct 2022
|
|
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly
Zacks via Yahoo Finance
20 Oct 2022
|
|
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
Zacks via Yahoo Finance
19 Oct 2022
|
|
Why Akouos Stock Is on Fire Today
Motley Fool
18 Oct 2022
|
|
Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session...
Investing.com
18 Oct 2022
|
|
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
MarketWatch
18 Oct 2022
|
|
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Zacks via Yahoo Finance
10 Oct 2022
|
|
FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss
Benzinga via Yahoo Finance
13 Sep 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 36.93M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$88.50M |
| EBIT | -$92.59M |
| Net Income | -$92.59M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 4.92 |
| Cash/Share | 2.11 |
| EPS | -$2.51 |
|---|---|
| ROA | -36.86% |
| ROE | -45.09% |
| Debt/Equity | 0.19 |
|---|---|
| Net debt/EBITDA | 0.38 |
| Current ratio | 17.30 |
| Quick ratio | 17.30 |